Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts-Reference-Cited by-同舟云学术

Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts

Published:2015-12 Issue: Volume:153 Page:136-142
ISSN:0162-0134
Container-title:Journal of Inorganic Biochemistry
language:en
Short-container-title:Journal of Inorganic Biochemistry

Author:

Messori Luigi,Marzo Tiziano,Merlino Antonello

Funder

Beneficentia Stiftung

European Cooperation in Science and Technology

Publisher

Elsevier BV

Subject

Inorganic Chemistry,Biochemistry

Reference51 articles.

1. Cellular processing of platinum anticancer drugs

2. Molecular mechanisms of resistance and toxicity associated with platinating agents

3. DNA Modifications by antitumor platinum and ruthenium compounds: Their recognition and repair

4. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA

5. Exploring Metallodrug–Protein Interactions by ESI Mass Spectrometry: The Reaction of Anticancer Platinum Drugs with Horse Heart Cytochrome c

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Picoplatin binding to proteins: X-ray structures and mass spectrometry data on the adducts with lysozyme and ribonuclease A;Dalton Transactions;2024

2. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity—a perspective overview;BioMetals;2023-11-06

3. Inorganic Drugs as a Tool for Protein Structure Solving and Studies on Conformational Changes;Chemistry – A European Journal;2023-01-30

4. In silico investigation of organometallic complexes for identification of RNase A inhibitor;Journal of Organometallic Chemistry;2023-01

5. Interaction of V^IVO–8-hydroxyquinoline species with RNase A: the effect of metal ligands in the protein adduct stabilization;Inorganic Chemistry Frontiers;2023